Drug Profile
Ixazomib - Takeda Oncology
Alternative Names: Ixazomib citrate; MLN-2238; MLN-9708; NINLAROLatest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals; University of California, San Diego
- Developer Celgene Corporation; Helsinki University Central Hospital; HOVON Foundation; Massachusetts General Hospital; National Cancer Institute (USA); Northside Hospital; Northwestern University; Takeda Oncology; University of Texas M. D. Anderson Cancer Center
- Class Amides; Antineoplastics; Antivirals; Chlorobenzenes; Organic boron compounds; Small molecules
- Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Phase III Amyloid light-chain amyloidosis
- Phase II Acute myeloid leukaemia; Amyloidosis; Follicular lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Phase I/II HIV infections
- No development reported Lupus nephritis; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
- Discontinued Bladder cancer; Solid tumours
Most Recent Events
- 29 Nov 2023 Millennium Pharmaceuticals and Takeda completes a phase-III clinical trials in Multiple myeloma (Newly diagnosed, Second-line therapy or greater) in China, Germany, Belgium, Czech Republic, Austria, Portugal, Denmark, Spain, Sweden, Hungary, France, Greece, Croatia, Poland, Italy (PO) (NCT03748953) (EudraCt2014-001394-13)
- 31 Oct 2023 Takeda completes a phase I/II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in the USA (NCT02206425)
- 19 Oct 2023 Takeda terminates a phase II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater, Newly diagnosed, Maintenance therapy) in USA (PO) due to insufficient enrollment (NCT03733691)